Report

Mode of Action

The electronic module creates an ionic stream through the patient. The Lectroject System emits a particle which follows the ionic stream to the + electrode. A small quantity of Acyclovir is placed under the applicator pads. The particle tacks through the Acyclovir, collects an atom of the medication and deposits in the affected cell where it interferes with the viral DNA and so prevents replication, the virus becomes dormant and is eventually eliminated from the body in a normal way. (By catabolism)

Action of Medication in Herpes

The anti-viral Acyclovir is picked up by the particles and carried through the skin into the cell; it is phosphylated to Acyclovir triphosphate. The first step in this process depends on the presence of HSV coded thymidine kinase. Thymidine kinase converts Acyclovir into a monophosphate. The monophosphate is further converted to diphosphate by cellular guanylate kinase and triphosphate which interferes with HSV DNA polymerase and inhibits viral DNA replication.

Mode of Action in Influenza

The influenza cycle begins with viral entrapment in secretions, the virus attaches through haemaglutinin to the receptors. The virus then penetrates the host cell. The next step is transcription of viral poteins. Replication of viral RNA. Virion release from host cell by neuraminidase, which is an enzyme essential for replication in vivo and allows the release of the virus from infected cells. Acyclovir inhibits influenza virus neuraminidase and so prevents the virus from escaping and infecting other cells.

News Flash

During January/February 2005 a patient suffering from HIV/Aids was treated over a period of 10 days. During this time his viral load was reduced from 170,000 particles to 92,000 particles. This does not imply that Lectroject can cure Aids as large-scale trials will have to be carried out, however it shows a commitment to continuing research by the inventors. Once again we stress that the above result was seen in ONE individual and that no claims are made concerning Aids.

Research

South African and American researchers are joining forces in an attempt to prove that a drug, already in generic form and already taken by 40 million people, is the key to keeping HIV-negative people negative, in spite of their HIV-positive partners.

The drug being tested is acyclovir, which was licensed by US Food and Drug Administration in 1983. It is widely used for treating genital herpes and has been found to be safe and effective in patients who have taken it daily for up to nine years.

At the crux of the study is genital herpes, a virus which infects as many as 80 percent of HIV-positive people, and about half of those who are negative, making it one of the most common sexually-transmitted infections here and across Africa.

The link with the spread of HIV is obvious from research that has shown that people with the genital herpes virus HSV-2 are twice as likely to get HIV, compared to those who do not have genital herpes.

People who are HIV positive and have genital herpes are five times more likely to transmit HIV to their partner.

Professor Connie Celum, professor of medicine at the University of Washington, and the study’s principal investigator, told a press conference that for every couple where one partner is HIV-positive, there was, on average, a 50-50 chance that the other partner would be negative.

This study is funded by the Bill and Melinda Gates Foundation and here has been approved by the SA Medical Control Council.

FREE with every Lectroject machine!

With every Lectroject machine you buy you get one (sample) tube 2g Acyclovir Topical cream and 20 Lectroject Applicator Pads ABSOLUTELY FREE!!